These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34989088)
1. Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'. Doumas M; Patoulias D; Papadopoulos C Eur J Heart Fail; 2022 Feb; 24(2):400-401. PubMed ID: 34989088 [No Abstract] [Full Text] [Related]
2. Reply to 'Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in subjects with heart failure?' Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'. De Biase N; Del Punta L; Pugliese NR Eur J Heart Fail; 2022 Feb; 24(2):401. PubMed ID: 34985799 [No Abstract] [Full Text] [Related]
3. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure. Crea F Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617 [No Abstract] [Full Text] [Related]
5. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction. Berendse J; Newenhouse L S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574 [No Abstract] [Full Text] [Related]
6. Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)? Katsiki N; Mikhailidis DP J Diabetes Complications; 2019 Nov; 33(11):107408. PubMed ID: 31522962 [No Abstract] [Full Text] [Related]
7. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors? Berezin AE; Berezin AA Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880 [TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future. Nana M; Morgan H; Bondugulapati LNR Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487 [TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango. Bauersachs J; Soltani S Eur Heart J; 2023 Oct; 44(37):3697-3699. PubMed ID: 37611060 [No Abstract] [Full Text] [Related]
12. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors. Crea F Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881 [No Abstract] [Full Text] [Related]
15. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction? Petrie MC; Lee MMY; Docherty KF Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794 [No Abstract] [Full Text] [Related]
16. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744 [TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved. Afsar B; Afsar RE Clin Nutr; 2023 Dec; 42(12):2338-2352. PubMed ID: 37862820 [TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure. Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145 [No Abstract] [Full Text] [Related]
20. Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes. Burgeiro A; Fuhrmann A; Cherian S; Espinoza D; Jarak I; Carvalho RA; Loureiro M; Patrício M; Antunes M; Carvalho E Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E550-64. PubMed ID: 26814014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]